UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  


FORM 8-K 

  


CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 11, 2016


 

Interpace Diagnostics Group, Inc.

(Exact name of registrant as specified in its charter) 

  


Delaware

 

000-24249

 

22-2919486

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

  

Morris Corporate Center 1, Building A

300 Interpace Parkway

Parsippany, NJ 07054

(Address, including zip code, of Principal Executive Offices)

 

(862) 207-7800

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

  


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 

 

  

Item 7.01. Regulation FD Disclosure.

 

Interpace Diagnostics Group, Inc. (the “Company”) is furnishing an Investor Presentation (the “Investor Presentation”), attached hereto as Exhibit 99.1, which the Company may use from time to time in presentations to investors and other stakeholders. The Investor Presentation will also be available on the Company’s investor relations webpage at http://www.interpacediagnostics.com.

 

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

  

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

99.1

Investor Presentation dated January 2016 (furnished and not filed for purposes of Item 7.01)

 

 

 
 

 

 

signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Interpace Diagnostics Group, Inc.

 

 

 

 

 

 

 

 

 

Date: January 11, 2016

By:

/s/ Graham G. Miao

 

 

 

Graham G. Miao

 

 

 

Executive Vice President, Chief Financial Officer, Treasurer and Secretary

 

 

 

 
 

 

  

exhibit INDEX

 

EXHIBIT
NUMBER

DESCRIPTION

99.1

Investor Presentation dated January 2016 (furnished and not filed for purposes of Item 7.01)